“Translating Genetic Findings and Decoding Genes for Better Health and Patient care”
Eurofins Clinical Genetics India (ECGI) is among the pioneers in molecular genetic testing and carrier screening for health and patient care using high throughput next-generation sequencing (NGS) technologies in India. ECGI strives to make the molecular genetic testing process affordable and efficient with actionable information for clinicians, patient and researchers. The ECGI team and its collaborators across the globe have rich expertise and experience in implementation of Omics technologies to create innovative solutions for clinical genomics and genetics to improve patient’s outcome. ECGI helps decode the cause of disease at base level of DNA by applying big data analytic platform and building the biological database to provide a simplified report to the clinician to understand and manage genetic disorders.

Laboratory infrastructure at Eurofins meets national and international standards for clinical genetic services like exome sequencing, mendelian panel testing, non-invasive prenatal screening (NIPS), genetic testing panels, carrier screening, MLPA testing, CGH array testing and many more to come.

ECGI is a part of Eurofins Scientific, which is the world leader in genomics, diagnostics, food, environment and pharmaceutical products testing. It is also one of the global market leaders in agro science, discovery pharmacology and central reference laboratory services. Eurofins has over 40,000 staff and 400 laboratories across 44 countries. Eurofins Clinical Genetics India Pvt. Ltd. is a NABL compliance, ISO 9001:2015 certified and GLP accredited company.

Our mission is to provide affordable genetic testing on innovative next generation technologies to decode rare genetic condition to improve and maintain health and wellness.
PreNatSure \textsubscript{NIPS} is a simple non-invasive genetic screening test which detects the chromosomal abnormalities that is Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), and Trisomy 13 (Patau Syndrome), Monosomy-X (Turner Syndrome), Tripple X Syndrome, Klinefelter Syndrome, Jacob Syndrome. in the fetus by Next-Generation Sequencing (NGS) of fetal cell-free DNA isolated from the maternal peripheral blood with quick report turn around time (1-2 weeks). Women with advanced maternal age (>35yrs), along with a positive serum screening result and abnormal ultrasound report, should undergo PreNatSure.

- **PreNatSure \textsubscript{NIPS}** can be done as early as 10 weeks of gestational age on singleton/twin pregnancy
- Only 1 tube of 10 ml blood is required for **PreNatSure \textsubscript{NIPS}**
- Can detect Aneuploidy at Fetal Fraction (cfDNA) as low as 1.4-2.7 %
- Proven technology with clinical experience on over 1,15,000 patients
- False positive and false negative rate as low as 0.2%
- **PreNatSure \textsubscript{NIPS}** works in Twin Pregnancies & Consanguineous marriages

* Eurofins Clinical Genetics strictly follows *"The Pre-natal diagnostics techniques (Regulation and prevention of misuse) Act, 1994*", no sex determination is done. Sex determination is punishable offence under Indian Penal Code.

---

The **ExomSure \textsubscript{Dx}** is the next level in medical exome sequencing offered by Eurofins Clinical Genetics India Pvt. Ltd. (ECGI). Most of the disease-associated genes (more than 22000 genes) are analyzed, having coverage 100% (with a mean read depth of 80-100X) of all exons. With the best using updated library preparation technique and proprietary variant database having well characterized and defined variants for better reporting. **ExomSure \textsubscript{Dx}\ text*** by ECGI is the most comprehensive exome sequencing test available in Indian market. The **ExomSure \textsubscript{Dx}** test can be carried out for Proband, Trios and additional family member, allowing clinicians to choose relevant disease associated gene related to patient’s phenotype.
ClinExomSure HMD

The ClinExomSure HMD is the proprietary in clinical exome sequencing technology which screens all the Mendelian inherited diseases such as Sickle cell anemia, Noonan syndrome, Tay Sachs, Cystic fibrosis etc. About 7000 disease-associated genes are analyzed, having maximum coverage up to 100% (with a mean read depth of 80-100X) of all exons are screened. With the best library preparation technique and proprietary variant database having well characterized and defined variants for better. ClinExomSure HMD is the most comprehensive and one of its kind exome sequencing screening test available in Indian market. The ClinExomSure HMD test can be carried out on individuals with a higher risk of disease predisposition, which allows clinicians to choose relevant disease associated genes related to patient’s phenotype.

MitoSure Screening

MitoSure Screening offers screening of mitochondrial genome to discover and understand the mitochondrial contribution (with an estimated frequency of 1:2000 to 1:5000) in genetic predisposition like Mitochondrial Encephalomyopathy, MILS, MELAS, LHON, MIDD, Mitochondrial Myopathy/Cardiomyopathy, CPEO. High throughput mitochondrial genome screening by NGS at an affordable price, enables the sequencing of hundreds of mitochondria for determination of most commonly occurring diseases with their heteroplasmy level.
Join us to Save Our Future Generation

An approach to comprehensive Thalassemia Gene Screening

ThalSure

ThalSure is an approach to screen the most commonly found causative mutation (a total number of 16 variants) in \textit{HBB} gene responsible for \(\beta\)-thalassemia in India. It offers a comprehensive family screening at an affordable cost for this particular condition which not only helps one to identify the disease, but also calculates the risk of inheriting the condition for each family member. ECGI provides free Genetic Counselling by professional qualified Genetic Counselors.

PanelSure

Panel\textsuperscript{Sure} \textsubscript{\textsuperscript{NGS}} is the best option to assess multiple genes in parallel, for identifying genetic change that may contribute to inherited risk for genetic diseases in families. ECGI offers approximately 50 panel testing including Woman Focused (eg. HBOC), ENT (eg, Hearing Loss, Retinitis Pigmentosa etc) Neuro & Neuro-Muscular (eg, DMD, LGMD etc.), Liver Diseases and other genetic disorder specific panels. The average number of gene covered in PanelSure varies from 50-200. One key feature of ECGI gene panels is "the design of the panel to cover the clinical significant regions associated with the diseases". This particular approach helps and enhances the clinical interpretation of causative variant in a patient at an economical price.
Multiple Ligand Dependent Probe Amplification (MLPA) screens all deletions and duplications in the gene of interest and also finds out the Copy Number Variations (CNVs) which has a greater impact on the majority of the genetic disorders. ECGI MLPA testing covers more than 10 diseases such as DMD, BMD, LGMD, Cystic Fibrosis, Glioma etc. associated with genomic DNA abnormalities for proper correlation of the disease phenotype and genotype. MLPA is one the most cost-effective, robust test method with shortest test reporting time.

The GeneticSure test is a custom simple gene test carried out by Sanger Sequencing which helps to identify if a person is a carrier for a genetic condition enabling the doctors to lay down proper healthcare management plan and reduces financial burden on the family. This is a simple cost effective blood test which can also be supplemented by advance molecular testing utilizing specific tissue or body fluids, giving the status of one’s gene signature compared to reference i.e. unaffected healthy person.

Newborn Screening is a health program of screening in infants shortly after birth for a list of conditions that can affect a child’s long-term health or survival, some of these are treatable, but not clinically evident in the newborn period. Some of the conditions included in newborn screening programs are only detectable after irreversible damage has been done, in some cases sudden death is the first manifestation of a disease. Early detection, diagnosis, and intervention can prevent death or disability and enable children to reach their healthy development. ECGI with MILS launched the NewbornSure-140+ marker Panel, NewbornSure-46+ marker Panel & NewbornSure-6 marker panel.
“Under the umbrella of GeneSure, ECGI has tried to bring series of test to confirm or rule out a suspected genetic conditions or help determine a person’s chance of developing or passing on a genetic disorder. Tests covered under GeneSure ranges from carrier screening to therapy evaluation with focus on various disease disorders like myopathy, cancer etc., giving the flexibility in the hands of clinician for various screening services.”

Routinely used in the clinical constitutional cytogenetic application, ArraySure is optimized for balanced whole-genome coverage, enabling high-resolution DNA copy number analysis with precise breakpoint accuracy as well as high-density SNP coverage for loss of heterozygosity (LOH) / absence of heterozygosity (AOH), long contiguous stretch of homozygosity (LCSH), and uniparental isodisomy (UPD) detection. ArraySure enables low-level mosaicism visualization, absence of heterozygosity (AOH) and acquired UPD (aUPD) detection, copy number change confirmation, triploidy detection, allelic imbalance pattern visualization, genomic contamination identification, and parent-of-origin analysis with genotype accuracy of > 99%.
Eurofin’s Worldclass Clinical Genetics Laboratories Across the World

Access ECGI on Mobile Devices..
ECGI on the go....

Eurofins Clinical Genetics India Pvt. Ltd.

Bangalore Office
#540/1, Doddanakundi Industrial Area 2, Hoodi, Whitefield, Bangalore 560048, Karnataka, India.
+91 9513520807, +91 80 30982500
salesecgi@eurofins.com
www.eurofinsclinicalgenetics.co.in

Mumbai Office
202-C, A-Wing, Sumit Samarth Arcade, Off Aarey Road, Opp. Goregaon Station, Goregaon West, Mumbai - 400062.
Customer Care: +91 9513800015
ECGI Sales: +91 9513520818